RenovoRx (RNXT) Revenue (2025 - 2026)
RenovoRx's (RNXT) quarterly Revenue came in at $909000.0 in Q2 2026, up 115.4% year-over-year from $422000.0 in Q2 2025, and up 61.46% quarter-over-quarter from $563000.0 in Q1 2026.
Powered by 
Analysis
RenovoRx (RNXT) Revenue (2025 - 2026) Analysis & Trends
RenovoRx has disclosed Revenue across 2 years of filings, most recently posting $909000.0 for Q2 2026.
- In Q2 2026, Revenue rose 115.4% year-over-year to $909000.0; the TTM figure through Jun 2026 stood at $2.0 million (changed N/A YoY), while the FY2025 annual figure was $1.1 million, up 2511.63% from the prior year.
- Revenue came in at $909000.0 for Q2 2026 at RenovoRx, up from $563000.0 in the prior quarter.
- In the past five years, Revenue ranged from a high of $909000.0 in Q2 2026 to a low of $197000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.55 Bn | 175.95 Bn | 7.27 Bn | 12.59 Bn |
| 2 | Intuitive Surgical | 127.61 Bn | 122.40 Bn | 1.96 Bn | 2.89 Bn |
| 3 | Medtronic | 117.18 Bn | 108.37 Bn | 6.34 Bn | 9.76 Bn |
| 4 | Stryker | 105.17 Bn | 101.69 Bn | 4.50 Bn | 6.59 Bn |
| 5 | Boston Scientific | 64.67 Bn | 64.13 Bn | 3.85 Bn | 5.44 Bn |
| 6 | Edwards Lifesciences | 49.86 Bn | 45.61 Bn | 1.35 Bn | 1.74 Bn |
| 7 | Alcon | 33.06 Bn | 31.60 Bn | 1.68 Bn | 2.78 Bn |
| 8 | Dexcom | 32.22 Bn | 30.27 Bn | 830.00 Mn | 1.31 Bn |
| 9 | Steris | 20.74 Bn | 20.26 Bn | 684.20 Mn | 1.49 Bn |
| 10 | RenovoRx | 90.81 Mn | 90.81 Mn | 766,000.00 | 909,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 909,000.00 |
| Mar 31, 2026 | 563,000.00 |
| Dec 31, 2025 | 238,000.00 |
| Sep 30, 2025 | 266,000.00 |
| Jun 30, 2025 | 422,000.00 |
| Mar 31, 2025 | 197,000.00 |